A phase III randomized study of BBI608 and best supportive care versus placebo and best supportive care in patients with pretreated advanced colorectal carcinoma.

 

Trial Summary:

The primary objective of CO.23 is to compare Overall Survival (OS), defined as the time from randomization until death from any cause, in patients with pre-treated advanced colorectal carcinoma treated with BBI608 plus best supportive care versus placebo plus best supportive care.

Supported By:

Boston Biomedical Inc

Eligibility:

Adults 18 and over. Histologically confirmed advanced colorectal cancer that is unresectable.

Registration ID:

ACTRN12613000556741

Participation:

International

Australian Lead Group:

 

Status:

close out

Activation Date:

27/08/2013

Chairs:

Dr Louise Nott

Contact:

co.23@ctc.usyd.edu.au